The multiplex PCR assays market is anticipated to be valued US$ 1.3 billion in 2023. The market is anticipated to grow at an 8.5% CAGR over the course of the forecast period, reaching US$ 3.0 million by 2033. The market for multiplex PCR assays has grown significantly in the last several years. The need for rapid and simultaneous detection of multiple pathogens or genetic markers, improvements in molecular diagnostics, and the growing demand for accurate and efficient diagnostic solutions are some of the factors driving this growth and impacting the size of the market.
The multiplex PCR assays market is expected to witness continued growth due to ongoing advancements in molecular diagnostics, increasing demand for point-of-care testing, and the development of targeted therapies. Additionally, the integration of multiplex PCR with other technologies, such as NGS and digital PCR, holds potential for further advancements in multiplex diagnostic capabilities.
Achieve Peak Productivity - Don't Delay Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17641
Multiplex PCR assays play a crucial role in infectious disease diagnostics by allowing the detection of multiple pathogens simultaneously. They are particularly useful in outbreaks, epidemiological studies, and surveillance programs. Multiplex PCR assays are widely used for respiratory infections, gastrointestinal infections, sexually transmitted infections, and bloodstream infections.
The multiplex PCR assays market benefits from continuous advancements in technology. These include the development of high-throughput platforms, automation, improved primer design, multiplex probe-based assays, and the integration of PCR with other technologies such as next-generation sequencing (NGS) or microarrays. These advancements enhance the sensitivity, specificity, and scalability of multiplex PCR assays.
Key Takeaways:
- The multiplex PCR assays industry in the United States is predicted to reach US$ 740.9 million by 2033, increasing at a 7.1% CAGR.
- The multiplex PCR assays industry in the United Kingdom is estimated to reach a market value of US$ 146.9 million, expanding at a CAGR of 8.7% by 2033.
- During the forecast period, the multiplex PCR assays industry in China is expected to reach a market value of US$ 188.7 million, securing an 6.6% CAGR.
- The multiplex PCR assays industry in Japan is predicted to reach US$ 115.0 million by 2033, increasing at a 7.0% CAGR.
- South Korea's multiplex PCR assays industry is predicted to achieve a market share of 1.8%, rising at a 4.7% CAGR during the forecast period.
- With a CAGR of 8.4% from 2023 to 2033, the Instrument is expected to dominate the multiplex PCR assays industry.
- With a CAGR of 7.9% from 2023 to 2033, the planar assay is expected to dominate the multiplex PCR assays industry.
- With a CAGR of 9.2% from 2023 to 2033, the research development is expected to dominate the multiplex PCR assays industry.
- With a CAGR of 9.9% from 2023 to 2033, the biopharmaceutical companies is expected to dominate the multiplex PCR assays industry.
Key Players:
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories
- QIAGEN
- Luminex Corporation
- Fluidigm Corporation
- BioFire Diagnostics.
Key Developments:
- In June 2021, Bio-Rad confirmed its agreement with Seegene to supply molecular testing services in the USA market.
Segmentation Analysis of the Multiplex PCR Assays Market
By Product Service:
- Consumables
- Instruments
- Software and Services
By Assay Type:
- Planar Assay
- Blends Protein Arrays (Multiplexed ELISA)
- Antibody Arrays
- Bead-based Assay
- Magnetic Bead-based
- Non-magnetic Bead-based
By Application:
- Disease Diagnosis
- Infectious Disease
- Cancer
- Autoimmune Disease
- Other Diseases
- Research and Development
- Other Application
By End User:
- Biopharmaceutical Companies
- Clinical Research Organizations
- Academic Research Institutes
- Diagnostic Centers
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East Africa